Regulated HealthTech PMF: Building Patient Orchestration Platforms with Dr. Kal Patel

Regulated HealthTech PMF: Building Patient Orchestration Platforms with Dr. Kal Patel

Join Dr. Kal Patel, CEO and Co-Founder of BrightInsight, for an illuminating masterclass on navigating product-market fit (PMF) inside one of the most complex, highly regulated sectors in global business: healthcare. Every year, life science giants invest billions of dollars developing breakthrough biopharmaceutical therapies, yet nearly 50% of patients with chronic diseases drop off their prescribed medication regimes within the first twelve months. Drawing from his rare vantage point as a physician, former BCG strategist, former head of Amgen’s Digital Health unit, and leader of BrightInsight, Dr. Patel breaks down why traditional "direct-to-consumer" wellness apps repeatedly fail, how to build enterprise software that biopharma giants trust to touch regulated therapies. 🎯 Insights You’ll Learn: Unlocking PMF in Biopharma: Why finding true product-market fit in regulated healthcare requires solving for three distinct buyers simultaneously. The $300B Medication Adherence Deficit: How predictive digital interventions, automated onboarding concierges, and real-time patient companion apps prevent early therapy drop-off. The "Build vs. Buy" Trap in Enterprise Pharma: Why global biopharma companies historically wasted hundreds of millions building custom, one-off apps that failed to scale globally—and why standardized, compliant infrastructure wins. Predictive Patient Orchestration: How machine learning algorithms analyze behavioral signals to detect therapy discontinuation risks before a patient misses a dose. Navigating the Global Regulatory Matrix: The engineering architecture required to launch FDA-regulated software and Software as a Medical Device (SaMD) across 40+ countries without re-inventing regional compliance infrastructure. Real-World Evidence That Scales: How BrightInsight's real-world deployment with global partners like Sanofi and Regeneron demonstrated a measurable 4% decrease in patient discontinuation and real adherence gains. 🌍 Why This Matters: The healthcare industry is experiencing a profound structural shift: launching a revolutionary drug is no longer enough to guarantee commercial success or optimal patient outcomes. If a patient abandons a life-saving biologic due to daunting self-injection steps, unmanaged side effects, or prior-authorization friction, the science fails. Dr. Kal Patel is building the underlying connective tissue that fixes this broken pipeline. By providing a unified, regulated digital health platform that powers personalized companion apps, digital patient support programs (PSPs), and algorithm-driven interventions, BrightInsight ensures that patients stay on therapy longer—maximizing both clinical health outcomes and biopharma revenue. 👤 Expert Background: CEO & Co-Founder of BrightInsight, the leading regulated digital health patient orchestration platform for global biopharma and medtech. Founder & Former Head of Amgen's Digital Health Unit, where he established and scaled connected device programs and digital algorithms across a multi-billion-dollar portfolio. M.D. & MBA, holding a Doctor of Medicine from the University of Chicago Pritzker School of Medicine and an MBA from the Chicago Booth School of Business. 🎙️ Hosted by Gary Fowler, CEO of GSD Venture Studios — global AI entrepreneur, investor, and innovation leader spotlighting founders navigating the realities of building in the AI era. 💡 Perfect For: Biopharma commercial executives, digital health product leads, healthtech venture capital partners, chief medical officers, enterprise software architects, and founders scaling regulated B2B enterprise platforms. 🚀 Timely Topic: As biopharma companies reevaluate their software investments, point solutions and standalone apps are being replaced by unified, compliant orchestration platforms. Dr. Kal Patel provides the definitive product philosophy and operational execution model needed to bring digital health into main-stage healthcare delivery.

Growing the Future: Scaling White Biotech to Outperform Fossil Plastics with Jeroen van Rotterdam

Join Jeroen van Rotterdam, Co-Founder and CEO of Foamlab, for a deep dive into the industrial transition from extracted synthetic foams to bio-fabricated materials grown by nature. Every year, millions of tons of fossil-based plastic foams are manufactured for packaging, insulation, textiles, and automotive components—materials that generate persistent microplastic pollution and are virtually impossible to recycle economically. Jeroen explains why sustainability shouldn't be a trade-off, how white biotechnology yields materials with mechanical properties superior to petrochemical plastics, and how AI-driven bio-process optimization is accelerating the transition from laboratory Petri dishes to pilot-plant production scale. 🎯 Insights You’ll Learn: The White Biotech Imperative: Why replacing non-degradable polystyrene and polyurethane requires shifting from petroleum extraction to industrial fermentation using microorganisms. Bacterial Nanocellulose Platform: How bacteria consume simple sugars to synthesize high-purity cellulose networks that can be tuned into soft sponges, flexible textiles, or rigid load-bearing structural foams. AI-Accelerated Biomaterial Engineering: Utilizing artificial intelligence and neural predictive models to optimize fermentation parameters, strain performance, and structural foam density in days rather than years. Overcoming the Biotech Scale-Up Bottleneck: Lessons from raising €3 million in growth capital to build a pilot manufacturing plant, transition out of the lab, and navigate high-yield bioreactor engineering. Lessons from Enterprise Tech to Deep-Tech Biotech: How Jeroen’s executive leadership experience at Citrix, Dell/EMC, and enterprise software startups informs his pragmatic commercial approach to unit economics and beachhead market selection. 🌍 Why This Matters: Fossil-based foams like expanded polystyrene (Styrofoam) represent a $29 billion global market built on materials that persist in ecosystems for centuries. Merely tweaking traditional plastic formulations is no longer enough; industrial manufacturing requires a fundamental materials reset. Jeroen van Rotterdam and the team at Foamlab—a TU Delft spin-off—are proving that biology can cultivate materials that meet or exceed synthetic performance specs without environmental liabilities. By leveraging white biotech, automated fermentation tuning, and strategic pilot scale-ups, Foamlab provides a clear blueprint for turning greenhouse-intensive supply chains into circular, bio-based loops. 👤 Expert Background: Co-Founder & CEO of Foamlab, a Netherlands-based biotech startup scaling high-performance, fully compostable bio-based foams grown from bacterial cellulose. Former Executive Vice President of Engineering, Cloud, and Security at Citrix, and former executive at Dell/EMC. Serial Tech Entrepreneur & Angel Investor, who previously founded X-Hive (acquired by EMC) and actively supports deep-tech and sustainable materials startups. 🎙️ Hosted by Gary Fowler, CEO of GSD Venture Studios — global AI entrepreneur, investor, and innovation leader spotlighting founders navigating the realities of building in the AI era. 💡 Perfect For: Biotech investors, circular economy directors, materials science researchers, industrial packaging architects, automotive/aerospace supply chain leads, and deep-tech founders navigating pilot facility scale-ups. 🚀 Timely Topic: As international regulations tighten around single-use plastics and microplastic pollution, the competitive edge belongs to companies that can supply high-performing, bio-fabricated alternatives at industrial scale. Jeroen van Rotterdam is sharing the exact operational and technological framework driving this shift in 2026. Subscribe for more global founder conversations from GSD Venture Studios: https://gsdvs.com #WhiteBiotech #Biomaterials #Foamlab #Fermentation #CircularEconomy #DeepTech #JeroenVanRotterdam #GaryFowler #GSDVentureStudios

Why Dates Are Overhauling the Sweetener Market with Dr. Sylvie Charles Royston

Join Dr. Sylvie Charles Royston, Founder and CEO of Just Date, for an inspiring conversation on leaving clinical medicine to fix the root cause of chronic illness. As a practicing physician at UCSF treating patients suffering from preventable, sugar-driven conditions like type 2 diabetes and fatty liver disease, Sylvie realized that treating symptoms in a hospital clinic wasn't enough—the systemic solution belonged in the grocery aisle. In this episode, we explore how she translated her clinical medical training and culinary roots into an organic, date-based sweetener empire, expanding from her home kitchen into over 6,000 retail doors nationwide. 🎯 Insights You’ll Learn: The Clinical Pivot: Why seeing the daily public health impact of refined sugar on UCSF patients inspired Dr. Royston to leave a traditional medical career to fix metabolic health at the source. Immediate Product-Market Fit: The operational journey of moving from small-batch kitchen iterations to landing nationwide distribution in Whole Foods just weeks after launch. The Science of Date Sweeteners: How whole, upcycled organic dates deliver a low-glycemic, antioxidant-rich alternative that avoids blood sugar spikes without sacrificing taste or culinary performance. Category Innovation with Chocolate Chips: The strategic decision to disrupt the baking aisle by launching date-sweetened dark chocolate chips, expanding date syrup from a liquid sweetener into a multi-category platform. Scaling Mission-Driven CPG: Overcoming supply chain bottlenecks, navigating retail channel strategy across Sprouts, Kroger, and Natural Grocers, and building a female-led, sustainable food brand. Everyday Public Health: How Dr. Royston bridges clinical science with accessible family nutrition to protect children's physical and mental health from hidden sugar crashes. 🌍 Why This Matters: Over a third of the U.S. population suffers from pre-diabetes or diabetes, yet most "healthy" sugar alternatives rely on synthetic artificial sweeteners or heavily processed sugar alcohols that disrupt gut health. Dr. Sylvie Charles Royston is solving this nutritional dilemma by turning nutrient-dense dates—a staple of her childhood—into a versatile, clean-label ingredient platform. From launching nationwide distribution to forging strategic partnerships that fuel retail expansion, Just Date proves that food startups can scale rapidly while remaining fiercely committed to metabolic health, clean ingredients, and sustainable food systems. 👤 Expert Background: Founder & CEO of Just Date, the physician-founded food brand replacing refined sugar with nutrient-rich, date-based sweeteners and confections. Former UCSF Physician, who specialized in internal medicine and saw firsthand the urgent need for preventative, diet-based health solutions. National CPG Scale Operator, scaling Just Date into 6,000+ retail locations including Whole Foods, Sprouts, Kroger, and Natural Grocers. Health & Nutrition Advocate, recognized for pioneering low-glycemic food innovations that support family wellness and long-term metabolic health. 🎙️ Hosted by Gary Fowler, CEO of GSD Venture Studios — global AI entrepreneur, investor, and innovation leader spotlighting founders navigating the realities of building in the AI era. 💡 Perfect For: CPG founders, food and beverage investors, health and wellness advocates, retail buyers, and prospective entrepreneurs looking to scale mission-driven consumer products. 🚀 Timely Topic: As consumer demand for clean-label, low-sugar ingredients explodes, the future of CPG belongs to brands that combine rigorous science with uncompromised flavor. Dr. Sylvie Charles Royston is delivering the exact product and scaling blueprint driving that global movement. Subscribe for more global founder conversations from GSD Venture Studios: https://gsdvs.com #JustDate #HealthFood #CPG #Nutrition #DateSweetener #CleanIngredients #DrSylvieCharles #GaryFowler #GSDVentureStudios

Rethinking the Algorithm: Designing Safe Digital Spaces for Youth with Natalie Boll

Join Natalie Boll, Founder and CEO of Tribela, for an urgent and essential dialogue on reengineering the foundational blueprint of social media. After over two decades spent producing award-winning media content for CBC, Amazon, HGTV, and the Food Network, Natalie transitioned into technology to foster a healthier digital future. In this episode, we move past the uninspired debate of absolute youth device bans to explore how safety-by-design protocols, membership-backed business models, and humane design choices can co-exist to form a healthy, highly profitable digital environment for children and young people. 🎯 Insights You’ll Learn: The Attention Economy Detox: Why the traditional, advertising-driven business model inherently prioritizes toxic user engagement and infinite scroll over human wellness. The Membership Alternative: Moving away from data-harvesting and corporate ad reliance toward clean, subscription-supported digital spaces that remain highly commercially successful. The Oxford Incubator Playbook: How mapping global safety standards and ethical framework principles alongside Oxford University Innovation built a robust, enterprise-ready platform. Humane Technology in Practice: Applying core lessons from the Center for Humane Technology, Harvard Business School Online, and Oxford Saïd Business School to actual tech development. The Art of Storytelling to Tech Strategy: How a 20-year career creating award-winning media landscapes translates into building a highly engaging yet ethical social space. The Serial Founder Matrix: Lessons on balancing a diverse portfolio that spans cinematic production houses (Athene Films), organic skincare (Matinata), and deep-tech social architecture. 🌍 Why This Matters: In 2026, the psychological impact of algorithmically driven content loops on young minds is a globally recognized crisis. Yet, forcing kids completely offline isolates them from the very spaces where modern connection and creativity live. Natalie Boll refuses to accept that digital isolation or algorithmic exploitation are our only two choices. By constructing Tribela as a premium, membership-supported digital space rather than a data-harvesting machine, Natalie aligns company profitability directly with user peace of mind. Created with deep academic rigor and a mother’s perspective, Tribela proves that digital infrastructure can be constructed with contextual care, empathy, and long-term viability from day one. 👤 Expert Background: Founder & CEO of Tribela, an alternative, membership-backed social space pioneering safety-by-design for youth and communities. Award-Winning Executive Producer with a 20-year track record delivering premium storytelling across Amazon, CBC, and international networks. Oxford University Innovation Alumnus who incubated Tribela alongside leading global academic and ethical technology insights. Humane Tech Advocate trained via the Center for Humane Technology, Harvard Business School Online, and Oxford Saïd Business School. Multi-Hyphenate Entrepreneur behind Athene Films and the luxury organic skincare label Matinata. 🎙️ Hosted by Gary Fowler, CEO of GSD Venture Studios — global AI entrepreneur, investor, and innovation leader spotlighting founders navigating the realities of building in the AI era. 💡 Perfect For: EdTech investors, consumer tech product leads, child safety advocates, privacy compliance officers, and founders trying to align deep ethical design with sustainable, recurring subscription revenue. 🚀 Timely Topic: As international governments move closer to enforcing strict social media age limits and youth device regulations, the race is on for alternative, protected connection spaces. Natalie Boll is delivering the blueprint for an online architecture that honors human development instead of exploiting it. Subscribe for more global founder conversations from GSD Venture Studios: https://gsdvs.com #DigitalWellbeing #SafetyByDesign #EthicalTech #Tribela

Agentic Capital Markets: AI and Blockchain Transforming Private Markets with Edwin Mata

Join Edwin Mata, CEO and Co-Founder of Brickken, for a forward-looking examination of the structural migration reshaping global private finance. For years, traditional private capital markets have remained plagued by manual legal paperwork, siloed asset registries, and illiquid secondary trading loops. While the first wave of real-world asset (RWA) tokenization successfully demonstrated how Web3 rails can represent equity, debt, and real estate on-chain, Edwin argues that tokenization alone is just the preliminary step. Drawing from his background in M&A corporate law and Web3 systems architecture, Edwin details how Brickken is building the operational asset layer for "Agentic Capital Markets"—a paradigm shift where machine-readable financial assets, programmatic compliance standards like ERC-7943, and autonomous AI agents converge to execute end-to-end asset issuance, investor onboarding, and cross-border capital allocation. 🎯 Insights You’ll Learn: The Agentic Capital Market Shift: Moving past static token issuance to build machine-readable financial instruments that autonomous AI agents can query, trade, and manage. Standardizing Institutional RWA: How pioneering Ethereum standards like ERC-7943 embed regulatory compliance, transfer restrictions, and jurisdiction-aware logic directly into asset smart contracts. Autonomous Investor Operations: Replacing manual KYC/AML tracking and accredited investor verification with automated, on-chain identity verification and dynamic rule enforcement. AI-Driven Market Discovery: How autonomous agents leverage cross-chain data feeds to identify capital mispricings, evaluate private credit yields, and execute instant liquidity matching. 🌍 Why This Matters: Private markets represent hundreds of trillions of dollars in illiquid value, yet capital allocation remains severely bottlenecked by slow administrative overhead, fragmented geographic silos, and high intermediary costs. Edwin Mata is solving this institutional friction point at its core. Under his leadership, Brickken has grown into a leading institutional infrastructure provider that powers the entire lifecycle of real-world asset tokenization. By engineering the underlying compliance protocols and developer infrastructure required for AI agents to operate on-chain safely, Edwin is opening the door for 24/7 global liquidity, automated portfolio rebalancing, and democratized access to institutional-grade private assets. 👤 Expert Background: CEO & Co-Founder of Brickken, a leading global infrastructure provider enabling the compliant tokenization, management, and distribution of real-world assets. Cross-Border M&A & Technology Attorney, who specialized in international corporate transactions and regulatory frameworks prior to founding Brickken. Institutional Standard Co-Architect, actively driving the development and adoption of open Ethereum standards like ERC-7943 for institutional RWA interoperability. Global Web3 Keynote Speaker & University Lecturer, recognized as a leading voice on digital securities regulation, asset-backed tokens, and AI-driven financial markets. 🎙️ Hosted by Gary Fowler, CEO of GSD Venture Studios — global AI entrepreneur, investor, and innovation leader spotlighting founders navigating the realities of building in the AI era. 💡 Perfect For: Chief Investment Officers, Asset Management Directors, Private Equity Partners, FinTech Product Architects, Web3 Infrastructure Developers, and Venture Capitalists tracking the convergence of artificial intelligence, blockchain rails, and institutional private markets. 🚀 Timely Topic: As institutional appetite for real-world asset tokenization expands rapidly in 2026, the key competitive bottleneck is no longer issuing tokens, but enabling intelligent systems to trade and manage them safely. Edwin Mata is delivering the definitive blueprint and technical infrastructure required to build agentic financial markets.